Skip to content

洋洋医汇 Generic drug intelligence

Information resource for healthcare professionals and licensed importers. Not medical advice. No direct-to-consumer sales of prescription medicines.

All molecules (32)

Every monograph includes approved indications, mechanism, standard dosing and adjustments, side effects and monitoring, the generic/biosimilar manufacturer landscape, Southeast Asian availability, and the registration and strength details of each brand.

32 molecules

Osimertinib High demand

Originator: Tagrisso · AstraZeneca

Adjuvant therapy after tumor resection in adults with NSCLC whose tumors have EGFR exon 19 delet

Crizotinib High demand

Originator: Xalkori · Pfizer

Treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplast

Originator: Alecensa · Roche (Genentech in the US; originated by Chugai Pharmaceutical)

Adjuvant treatment in adult patients following tumor resection of ALK-positive non-small cell lu

Originator: Gavreto · Discovered by Blueprint Medicines; co-commercialised with Genentech (Roche) in the US and by Roche ex-US; Blueprint regained global rights (excluding Greater China) in 2023

Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detecte

Originator: Tabrecta · Novartis (discovered by Incyte, licensed to Novartis in 2009)

Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation

Originator: Lumakras · Amgen

As a single agent: adult patients with KRAS G12C-mutated locally advanced or metastatic non-smal

Originator: Lorbrena · Pfizer Inc.

Metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kin

Originator: Avastin · Genentech, Inc. / F. Hoffmann-La Roche Ltd

Metastatic colorectal cancer (mCRC) in combination with intravenous fluorouracil-based chemother

Originator: Herceptin · Genentech, Inc. / F. Hoffmann-La Roche Ltd

Adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with

Palbociclib High demand

Originator: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)

In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal

Originator: Verzenio · Eli Lilly and Company (Lilly USA, LLC)

In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant tre

Olaparib High demand

Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)

Maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BR

Originator: Zejula · GlaxoSmithKline (GSK); originally developed by Tesaro (Tesaro UK Limited)

Maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary per

Ibrutinib High demand

Originator: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC

Adult patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) - FDA

Originator: Rituxan · Genentech, Inc. (a member of the Roche Group), with Biogen; Rituxan is jointly marketed by Biogen and Genentech USA in the US; MabThera is marketed by Roche

Non-Hodgkin's lymphoma (NHL): relapsed or refractory, low-grade or follicular, CD20-positive B-c

Originator: Aubagio · Genzyme Corporation, a Sanofi company (US label lists Genzyme Corporation, Cambridge, MA; Sanofi markets Aubagio)

FDA: treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated synd

Adalimumab High demand

Originator: Humira · AbbVie (originally developed and marketed by Abbott Laboratories; initial U.S. approval 2002)

Rheumatoid arthritis: moderately to severely active RA in adults — reduces signs/symptoms, induc

Tofacitinib High demand

Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)

Rheumatoid arthritis: moderately to severely active RA in adults who have had an inadequate resp

Originator: Olumiant · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018)

Rheumatoid arthritis: moderately to severely active RA in adults who have had an inadequate resp

Originator: Remicade · Janssen Biotech / Johnson & Johnson (originally Centocor); initial U.S. approval 1998

Crohn's disease: reducing signs and symptoms and inducing and maintaining clinical remission in

Sofosbuvir/Velpatasvir High demand

Originator: Epclusa · Gilead Sciences (Gilead Sciences Ireland UC for the EU)

US (FDA): treatment of adults and pediatric patients 3 years of age and older with chronic HCV g

Sitagliptin High demand

Originator: Januvia · Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc.

US (FDA): adjunct to diet and exercise to improve glycemic control in adults with type 2 diabete

Originator: Galvus · Novartis

EU (EMA / UK SmPC): treatment of type 2 diabetes mellitus in adults as monotherapy in patients i

Originator: Tradjenta · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets)

US (FDA): adjunct to diet and exercise to improve glycemic control in adults with type 2 diabete

Dapagliflozin High demand

Originator: Forxiga · AstraZeneca (originally developed with Bristol-Myers Squibb)

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes me

Empagliflozin High demand

Originator: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)

To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with

Originator: Invokana · Janssen Pharmaceuticals (Johnson & Johnson), licensed from Mitsubishi Tanabe Pharma

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes me

Originator: Actos; Actoplus Met and Actoplus Met XR · Takeda Pharmaceutical Company (first US approval 1999)

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes me

Originator: Victoza · Novo Nordisk

As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients

Insulin Glargine High demand

Originator: Lantus · Sanofi

To improve glycemic control in adult and pediatric patients with diabetes mellitus (Lantus, US l

Insulin Degludec

Originator: Tresiba · Novo Nordisk

To improve glycemic control in adults with diabetes mellitus (US label of 2015)

Originator: NovoRapid · Novo Nordisk

To improve glycemic control in adults and children with diabetes mellitus (NovoLog, US label)

Therapeutic areas

Need a verified quotation?

Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.

Request a quotation

We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.

WeChat QR code

Scan to chat on WeChat

(placeholder image — final QR code pending)

Replace with the live WeChat QR before launch